BVD-523 is a small-molecule inhibitor of ERK kinase that has completed phase I testing and has demonstrated activity in patients with BRAF/MEK-inhibitor refractory, BRAF-mutant melanoma as well as in a patient with NRAS-mutant melanoma with a reasonable safety profile (15). Here, NRAS is linked to melanoma.